Japan Cell Culture Media Market Size & Outlook, 2026-2033
- Biotechnology
- Cell Culture & Stem Cell
- Cell Culture Media Market Outlook
- Cell Culture & Stem Cell
Global Market
Related Markets
Ask a question about the cell culture media market
Japan cell culture media market highlights
- The Japan cell culture media market generated a revenue of USD 184.1 million in 2024 and is expected to reach USD 513.0 million by 2033.
- The Japan market is expected to grow at a CAGR of 12.4% from 2025 to 2033.
- In terms of segment, serum-free media was the largest revenue generating product in 2024.
- Serum-free Media is the most lucrative product segment registering the fastest growth during the forecast period.
Cell culture media market data book summary
| Market revenue in 2024 | USD 184.1 million |
| Market revenue in 2033 | USD 513.0 million |
| Growth rate | 12.4% (CAGR from 2025 to 2033) |
| Largest segment | Serum-free media |
| Fastest growing segment | Serum-free Media |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Serum-free Media, Chemically Defined Media, Specialty Media, Stem Cell Culture Media, Other Cell Culture Media, Classical Media, Immunology Media |
| Key market players worldwide | Sartorius AG, Danaher Corp, Merck KGaA, Thermo Fisher Scientific Inc, FUJIFILM Holdings Corp, Lonza Group Ltd, BD, STEMCELL Technologies, PromoCell GmbH, Cell Biologics, Inc. |
Other key industry trends
- In terms of revenue, Japan accounted for 4.3% of the global cell culture media market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China cell culture media market is projected to lead the regional market in terms of revenue in 2033.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,007.1 million by 2033.
There are two acts for regulation of regenerative medicines and cell therapy in Japan—The Act on the Safety of Regenerative Medicine (ASRM) and the Act on Pharmaceutical and Medical Devices (PMD Act). These two laws were enacted in November 2014. These laws fast track the process to the market for stem-cell-based treatments and other types of regenerative medicine.
The Act on the Safety of Regenerative Medicine allows operating players to register a therapy under one of three risk categories. Furthermore, it allows clinics and hospitals to commercialize cellular therapies without going through the usual kinds of trials to prove that a medicine is effective. It is mandatory for a hospital to have a cell processing facility certified by the Ministry of Health, Labor and Welfare to offer cellular therapies.
In addition, the Pharmaceutical and Medical Devices Act permits for conditional approval of therapies that have gone through some clinical testing. Companies are given the chance to promote a treatment across the country and get insurance payments; however, they are also required to gather additional efficacy data over a 7-year period.
No credit card required*
Publish Date: Aug 18, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell Culture Media Market Scope
Cell Culture Media Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| FUJIFILM Holdings Corp | View profile | 83,784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | www.fujifilmholdings.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Sartorius AG | View profile | 14,338 | Otto-Brenner-Strasse 20, Gottingen, NI, Germany, 37079 | www.sartorius.com |
| BD | View profile | 10001+ | Franklin Lakes, New Jersey, United States, North America | www.bd.com |
| PromoCell GmbH | View profile | 51-100 | Heidelberg, Baden-Wurttemberg, Germany, Europe | www.promocell.com/ |
| STEMCELL Technologies | View profile | 501-1000 | Vancouver, British Columbia, Canada, North America | www.stemcell.com |
| Cell Biologics, Inc. | View profile | 1-10 | Chicago, Illinois, United States, North America | www.cellbiologics.net |
Japan Cell Culture Media Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell Culture Media Market Outlook will help companies and investors design strategic landscapes.
Serum-Free Media was the largest segment with a revenue share of 36.07% in 2024.
Horizon Databook has segmented the Japan cell culture media market based on serum-free media, chemically defined media, specialty media, stem cell culture media, other cell culture media, classical media, immunology media covering the revenue growth of each sub-segment from 2021 to 2033.
There are two acts for regulation of regenerative medicines and cell therapy in Japan—The Act on the Safety of Regenerative Medicine (ASRM) and the Act on Pharmaceutical and Medical Devices (PMD Act). These two laws were enacted in November 2014. These laws fast track the process to the market for stem-cell-based treatments and other types of regenerative medicine.
The Act on the Safety of Regenerative Medicine allows operating players to register a therapy under one of three risk categories. Furthermore, it allows clinics and hospitals to commercialize cellular therapies without going through the usual kinds of trials to prove that a medicine is effective. It is mandatory for a hospital to have a cell processing facility certified by the Ministry of Health, Labor and Welfare to offer cellular therapies.
In addition, the Pharmaceutical and Medical Devices Act permits for conditional approval of therapies that have gone through some clinical testing. Companies are given the chance to promote a treatment across the country and get insurance payments; however, they are also required to gather additional efficacy data over a 7-year period.
- Japan Cell Culture Media Market Product Outlook (Revenue, USD Million , 2021-2033)
- Serum-free Media
- Chemically Defined Media
- Specialty Media
- Stem Cell Culture Media
- Other Cell Culture Media
- Classical Media
- Immunology Media
- Japan Cell Culture Media Market Application Outlook (Revenue, USD Million , 2021-2033)
- Drug Screening & Development
- Biopharmaceutical Production
- Diagnostics
- Tissue Engineering & Regenerative Medicine
- Other Applications
- Japan Cell Culture Media Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Research & Academic Institutes
- Hospitals & Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Other End Users
- Japan Cell Culture Media Market Type Outlook (Revenue, USD Million , 2021-2033)
- Semi-solid & Solid Media
- Liquid Media
Reasons to subscribe to Cell Culture Media Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell Culture Media Market Outlook databook
- Our clientele includes a mix of Cell Culture Media Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan Cell Culture Media Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Japan Cell Culture Media Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Japan Cell Culture Media Market, 2021-2033 (US$M)
Japan cell culture media market statistics, by product, 2021-2033 (US$M)
